Danaher Corporation $DHR Stock Sold by Milestones Administradora de Recursos Ltda.

Milestones Administradora de Recursos Ltda. trimmed its holdings in Danaher Corporation (NYSE:DHR) by 36.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 87,608 shares of the conglomerate’s stock after selling 50,181 shares during the quarter. Danaher makes up approximately 3.5% of Milestones Administradora de Recursos Ltda.’s portfolio, making the stock its 10th largest holding. Milestones Administradora de Recursos Ltda.’s holdings in Danaher were worth $19,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in DHR. BlackRock Inc. bought a new stake in shares of Danaher during the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC bought a new position in shares of Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher during the second quarter worth $1,287,949,000. Bank of America Corp DE bought a new position in shares of Danaher during the second quarter worth $993,846,000. Finally, Legal & General Group Plc purchased a new position in Danaher during the second quarter valued at $801,056,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Adjusted EPS beat expectations: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Profitability was supported by strength in the Biotechnology segment. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: Full-year outlook raised: Management increased its 2026 adjusted EPS guidance to $8.57-$8.62, above the prior outlook and analyst expectations. The improved forecast signals confidence that customer demand and operating trends are continuing to recover. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Biotechnology momentum improved: Biotechnology orders grew at a mid-teens rate in the quarter, while management described improving trends across end markets. Danaher also said it has the technological “building blocks” to pursue future growth from artificial intelligence in drug discovery. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: Revenue was broadly on target: Third-quarter revenue rose 8.3% year over year to $6.55 billion, just below the $6.56 billion consensus. The near miss was outweighed by the earnings and guidance beats but limits the evidence of a broad-based sales acceleration. Danaher’s Q3 2026 Earnings Results
• Negative Sentiment: Mixed segment performance and leadership uncertainty remain risks: The Masimo acquisition helped offset declines in respiratory diagnostic sales, while investors continue to assess the implications of Danaher’s CEO transition. These issues could restrain the stock if weaker businesses do not stabilize. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales

Danaher Stock Up 4.3%

NYSE DHR opened at $233.99 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a market capitalization of $164.49 billion, a P/E ratio of 41.56, a P/E/G ratio of 2.82 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a 50 day moving average price of $215.25 and a 200-day moving average price of $196.84.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. During the same period last year, the firm posted $1.89 earnings per share. Danaher’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on DHR shares. Royal Bank Of Canada lifted their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Wells Fargo & Company decreased their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Barclays raised their price objective on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.